Protocol Ledger

Therapeutic Cohort GAS · ClinicalTrials.gov API v2

Gastroenterology, Hepatology, and Renal: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 1,088 interventional Phase II and Phase III Gastroenterology, Hepatology, and Renal protocols registered from 2018 through 2026, including 422 active studies, 396 completed studies, and 140 early-stopped studies (12.87% overall; 26.12% of closed trials).

Median Enrollment: 76.0 participants Median Completed Span: 663 days California Share: 262 studies (24.1%)

1. Reconciled Gastroenterology, Hepatology, and Renal Execution & Stop-Cause Profile

Gastroenterology, Hepatology, and Renal Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 1,088 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 422 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 396 / 140 26.12% closed-trial attrition ratio across 536 closed protocols
Slow Accrual vs Safety & Futility Stops 33 / 15 / 13 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 71.5% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Gastroenterology, Hepatology, and Renal

Consolidated Biopharma, Academic & Federal Sponsors (Gastroenterology, Hepatology, and Renal Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
Mirum Pharmaceuticals Biopharma Industry 16 8 6 0
Zealand Pharma Biopharma Industry 16 2 13 1

3. Representative Multi-Center Phase II & III Gastroenterology, Hepatology, and Renal Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Gastroenterology, Hepatology, and Renal
NCT Study Protocol Brief Title Sponsor Phase Status
NCT07282353 A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA Cascade Pharmaceuticals Phase III RECRUITING
NCT05931276 CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes VA Office of Research and Development Phase III RECRUITING
NCT06470191 A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. Shanghai Jiaolian Drug Research and Development Co Phase II/III RECRUITING
NCT07803965 Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy Beijing Sungen Biomedical Technology Co Phase II RECRUITING
NCT06962800 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) Biogen Phase III RECRUITING
NCT06593392 Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus Vifor Fresenius Medical Care Renal Pharma Phase II RECRUITING
NCT05457283 A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Yea Bayer Phase III RECRUITING
NCT06933472 A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China Alebund Pharmaceuticals Phase III RECRUITING
NCT07159841 A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) Crinetics Pharmaceuticals Phase II/III RECRUITING
NCT04924868 Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis Hospital General Universitario de Alicante Phase III RECRUITING
NCT03949855 Belimumab With Rituximab for Primary Membranous Nephropathy National Institute of Allergy and Infectious Diseases (NIAID) Phase II RECRUITING
NCT06080789 A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis Panafina Phase II RECRUITING
NCT06466785 A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis Genexine Phase III RECRUITING
NCT03684278 Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I) University of Liverpool Phase II RECRUITING
NCT06963827 A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy Takeda Phase III RECRUITING
NCT07387549 A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis Ipsen Phase III RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI